How effective is pemetinib (pemetinib) targeted therapy and how much does it cost?

Pemetinib (pemetinib) is an innovative targeted therapy that brings a new treatment option to patients with cholangiocarcinoma. This drug has attracted widespread attention for its precise treatment of specific genetic mutations, especially for patients with cholangiocarcinoma with FGFR2 gene fusions or rearrangements.

The targeted therapy effect of pemetinib is remarkable, which has been verified in multiple clinical trials. For example, in the FIGHT-202 study, pemetinib showed durable tumor response, with an objective response rate of 37% and a median response duration of 8.1 months, indicating that the drug can stabilize the disease over a longer period of time. At the same time, the median progression-free survival and median overall survival also reached 7.0 months and 17.5 months respectively, which is an important breakthrough for patients with advanced cholangiocarcinoma.

In addition, the safety profile of pemetinib is relatively good. Although patients may experience some side effects, such as hyperphosphatemia, diarrhea, etc., most side effects are controllable and can be alleviated with appropriate medical management.

Pemetinib is currently on the market in China and patients can purchase it directly from domestic hospitals. The price of the original version of 4.5 mg 14 tablets is about 30,000 yuan. In foreign countries, the price of the original research version of 13.5 mg 14 tablets is as high as 72,000 yuan, but the generic version of Laos Lucius Pharmaceuticals with the same specifications only costs 850 yuan. If you need information about pemetinib, please consult a regular overseas medical company.

Overall, pemetinib (pemetinib), with its significant efficacy and relatively good safety profile, provides an effective targeted treatment option for patients with cholangiocarcinoma. The emergence of this drug not only extends the survival period of patients, but also improves the quality of life and brings new hope to the treatment of cholangiocarcinoma.